Almost all the headlines about Ocugen in the past year have been about the companys COVID-19 vaccine candidate. The FDA told the company in June 2021 that it should instead follow the standard path to full approval of the vaccine in adults. Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. The Motley Fool has no position in any of the stocks mentioned. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. If they invent a miracle treatment for a condition, the money will find its way to the stock. Don't overlook another approach, especially if you're still sitting on a nice gain even after last week's major sell-off. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad. Sign up below to get this incredible offer! Copy and paste multiple symbols separated by spaces. You canfollow Will on Twitterat @HealyWriting. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. 7 Travel Stocks to Buy Banking On Pent-Up Demand. What Is the Best EV Stock to Buy Now? MALVERN, Pa., May 29, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the 2018 BIO International Convention, taking place June 4-7, 2018, in Boston. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance COVAXINs development. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. However, I wont be around to find out. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. Why Ocugen Stock Is Crushing It Today | Nasdaq A $30 million market capitalization doesnt mean Ocugen has no chance. To make the world smarter, happier, and richer. All rights reserved. Even though Ocugen did raise $25 million in a private placement, the story behind OCU300 clearly was not enough to support an initial public offering on its own. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion - Stocktwits I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. CEO Shankar Musunuri stated that he was "pleased to say" that Ocugen was in discussions with the FDA about the data it had submitted for the pediatric EUA. This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. Keith Speights for What Is the Best EV Stock to Buy Now? In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. Histogenics shareholders then received about 14% of the company, according to the merger prospectus. However, sometimes the optimism isn't justified. At the beginning of 2020, Ocugen shares were trading at just 47 cents. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. The content is intended to be used for informational purposes only. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. The median estimate. It brings in no revenue. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The second is that the balance sheet still needs some help. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. Copyright The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. Keith Speights has no position in any of the stocks mentioned. In 2018, its NeoCart biologic failed to meet the primary endpoint of its own Phase III trial. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. Its certainly possible. Add in a $31 million market capitalization and potentially significant cash burn, and Ocugen stock self-evidently is not for risk-averse investors. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. Our 3 Top Picks. However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels. The FDA's decision not to issue EUA really wasn't all that surprising, though. As of 1:37 p.m. EST, the biopharmaceutical company's stock price was down more than 15%.. Shares of Ocugen ( OCGN -3.10%) fell on Tuesday after an analyst sounded a note of caution to investors. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. Importantly, neither Bharat nor Indian regulators revealed the efficacy of the vaccine. Ocugen. Nasdaq That's not going to happen now. These options will be cheaper than owning the stock itself. The all-time high Ocugen stock closing price was, The average Ocugen stock price for the last 52 weeks is. First, the balance sheet is in at least decent shape. Investors appear to expect that Bharat's big win for Covaxin in India could translate to success for Ocugen in the U.S. On Dec. 22, Ocugen and Bharat announced a binding letter of intent to jointly develop Covaxin for the U.S. market. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. Without NeoCart, that burn likely comes down. As of this writing, Vince Martin has no positions in any securities mentioned. Please check your download folder. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). Copyright 2023 InvestorPlace Media, LLC. ET on Friday. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. So, what goes wrong? Covaxin doesn't have an advantage in terms of dosing compared to these leading vaccines. OCGN Ocugen Inc 155,223 $0.9721 $0.0263 (2.63%) Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Investors should definitely reevaluate Ocugen's prospects in light of the company's bad news announced last week. If You Invested $1,000 In Ocugen Stock One Year Ago, Here's - Insider After all, one cannot expect Ocugen stock to cure its ills when the company itself has fallen into critical condition. Keith Speights for According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. UPDATE 1-Soccer-Traore on target as Wolves stun wasteful Spurs, Peruvian communities to resume blockade of crucial "mining corridor", One student loan forgiveness effort 'hasnt gotten the attention it deserves': expert, RPT-Death toll in strike on Ukraine's Zaporizhzhia rises to 11 - officials, Soccer-Traore on target as Wolves stun wasteful Spurs. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. Like other life sciences companies involved in Covid-19 vaccine. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. Do Not Sell My Personal Information (CA Residents Only). The Ocugen 52-week low stock price is 0.93, which is 1.1% below the current share price. Can you feel the ground moving beneath your feet? Copyright 2023 InvestorPlace Media, LLC. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. You can be a growth investor, futures trader, deep-value investor, a day trader, options player, or a dividend aficionado. Ocugen shares jumped to $3.50 on massive volume in December when the Covaxin partnership was announced. 2023 InvestorPlace Media, LLC. It's easy to become such a huge fan of a stock that you lose objectivity about its prospects. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. Weve now already seen a 50% correction in the stock price, with shares changing hands around 46 cents per share. The Nasdaq has been even more impressive, rallying 67.7% in the same time frame and hitting new all-time highs in the process. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. *Average returns of all recommendations since inception. Gw pharmaceuticals stock dividends will nike stock split soon CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants. Sign up below to get this incredible offer! Type a symbol or company name. Its top officers have experience at Pfizer (NYSE:PFE) and other well-respected pharmaceutical and biotechnology companies. For priority reviews, the timeline for an approval decision is reduced to six months. Nano-cap biotech play Ocugen has an intriguing story and a ton of risk. Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. It's hard to say for sure. The latest closing stock price for Ocugen as of March 03, 2023 is. Do not expect this to become the biotech who made good like Biogen (NASDAQ:BIIB). After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. But any success they find will be without me as a shareholder. Looking ahead, analysts are skeptical Covaxin will provide the upside Ocugen bulls are expecting. 7 Penny Stocks Poised for Explosive Growth in 2023, Ocugen Stock Is Not for the Faint of Heart. In that list, you can even include penny-stock trader. Some of the names will rally big, putting together epic squeezes that can double or triple the stock prices in just a few days. Ocugen: Peripheral Scandals Taint This Expired COVID-19 'Me-Too' Longshot Companies will inevitably be optimistic about their prospects for success (at least publicly). Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. As of this writing, Matt did not hold a position in any of theaforementioned securities. Its worth emphasizing: Ocugen stock is a play with enormous risk. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. To be sure, current cash isnt enough. Written by Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. The Ocugen 52-week high stock price is 4.03, which is 328.7% above the current share price. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. quotes delayed at least 15 minutes, all others at least 20 minutes. There's still a chance that the vaccine could receive a green light in Canada. The potential synergies of such a union do not seem clear. Still, Ocugens balance sheet isnt as dire as its share price might suggest. Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. Ill be sticking to the stocks that are actually working. Events - Ocugen See disclosure here. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. Start trading Options with Saxo today. Ocugen had to go an unusual route to go public. Type a symbol or company name. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. Matthew McCall left Wall Street toactually helpinvestors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. Theres an opportunity here. Ocugen completes $100M stock sale as it works with Bharat Biotech on The company has no revenue, runs an annual deficit, and does not generate positive free cash flow. There's a pretty good case to be made that other stocks offer even better prospects for returns with lower risk than Ocugen does. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. The stock ultimately hit its 2020 low on June 1 at a price of just 17 cents. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. Ocugen Stock Crashes: What Should Investors Do Now? Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. If you already owned Ocugen stock before the company's disappointing news, you have several alternatives. But there is no question some big-name stocks performed better than others along the way. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. That pathway will likely require the company to conduct further clinical testing of the vaccine in the U.S. Are there any other near-term catalysts for the biotech stock? The chances of anything more are small but the rewards could be huge. Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. How can we possibly evaluate a stock on a fundamental basis with that being reality? And its at least possible that OCGN could wind up being a winner. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. Moreover, Histogenics existed to treat orthopedic conditions, while Ocugen focused on rare eye diseases. Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. Ocugen estimates the drug could have as many as 63,000 potential patients. Unfortunately for longs, OCGN is much closer to the worst of conditions. OCGN Stock Forecast 2022 and 2025: Is Ocugen Set to Explode? Ocugen - Stock Price History | OCGN | MacroTrends 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Ocugen Stock Is Not for the Faint of Heart - InvestorPlace The Motley Fool has no position in any of the stocks mentioned. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Bharat Biotech has a history of successful vaccine commercialization in South Asia. If you missed that action, you missed all the gains. The market capitalization of Relmada Therapeutics (NASDAQ:RLMD) went from under $10 million at the end of 2017 to over $500 million at the moment. On June 10, though, Ocugen announced that the U.S. Food and Drug Administration (FDA) had effectively shut the door on an EUA filing. If Ocugen goes up, you can still profit. Investors were hopeful that the small drugmaker would be able to win U.S. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their. Even before that point, the most promising candidates generally can find funding. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. Don't Get Greedy With Ocugen Stock, Says Analyst The S&P 500 has rallied 52.9% from the March low to its highs on August 6. MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness.